Mcdavid Stilwell Acquires 3,700 Shares of Coherus BioSciences, Inc. (NASDAQ:CHRS) Stock

Thursday, June 10, 2021 | MarketBeat

Coherus BioSciences, Inc. (NASDAQ:CHRS) CFO Mcdavid Stilwell bought 3,700 shares of the stock in a transaction that occurred on Wednesday, June 9th. The shares were purchased at an average cost of $13.42 per share, with a total value of $49,654.00. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink.

Shares of NASDAQ CHRS traded up $0.52 during mid-day trading on Thursday, reaching $14.02. 799,949 shares of the company's stock traded hands, compared to its average volume of 1,162,378. The company has a market capitalization of $1.06 billion, a PE ratio of -11.07 and a beta of 1.08. The business has a 50-day moving average of $14.05. Coherus BioSciences, Inc. has a 1-year low of $12.90 and a 1-year high of $22.22. The company has a debt-to-equity ratio of 2.33, a quick ratio of 2.20 and a current ratio of 2.40.

Coherus BioSciences (NASDAQ:CHRS) last issued its quarterly earnings data on Thursday, May 6th. The biotechnology company reported ($2.37) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.09 by ($2.46). The business had revenue of $83.03 million for the quarter, compared to analyst estimates of $97.87 million. Coherus BioSciences had a negative net margin of 17.23% and a negative return on equity of 34.76%. As a group, sell-side analysts anticipate that Coherus BioSciences, Inc. will post -2.63 EPS for the current year.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Principal Financial Group Inc. grew its holdings in shares of Coherus BioSciences by 1.8% during the first quarter. Principal Financial Group Inc. now owns 557,032 shares of the biotechnology company's stock valued at $8,139,000 after buying an additional 10,018 shares during the last quarter. Millennium Management LLC acquired a new position in shares of Coherus BioSciences during the first quarter valued at about $5,894,000. Voloridge Investment Management LLC grew its holdings in shares of Coherus BioSciences by 30.7% during the first quarter. Voloridge Investment Management LLC now owns 264,882 shares of the biotechnology company's stock valued at $3,870,000 after buying an additional 62,159 shares during the last quarter. Morgan Stanley grew its holdings in shares of Coherus BioSciences by 19.2% during the first quarter. Morgan Stanley now owns 686,651 shares of the biotechnology company's stock valued at $10,032,000 after buying an additional 110,457 shares during the last quarter. Finally, Cubist Systematic Strategies LLC grew its holdings in shares of Coherus BioSciences by 554.7% during the first quarter. Cubist Systematic Strategies LLC now owns 71,366 shares of the biotechnology company's stock valued at $1,043,000 after buying an additional 60,466 shares during the last quarter.

CHRS has been the subject of a number of analyst reports. Barclays lowered their target price on shares of Coherus BioSciences from $28.00 to $24.00 and set an "overweight" rating for the company in a research note on Monday, May 17th. TheStreet downgraded shares of Coherus BioSciences from a "c" rating to a "d-" rating in a research note on Monday, May 17th. Maxim Group initiated coverage on shares of Coherus BioSciences in a research note on Friday, May 7th. They issued a "buy" rating and a $22.00 price target for the company. Zacks Investment Research downgraded shares of Coherus BioSciences from a "hold" rating to a "sell" rating in a research note on Friday, May 7th. Finally, HC Wainwright decreased their price target on shares of Coherus BioSciences from $29.00 to $26.00 and set a "buy" rating for the company in a research note on Thursday, May 13th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company's stock. Coherus BioSciences presently has a consensus rating of "Buy" and an average price target of $24.00.

About Coherus BioSciences

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its product candidate pipeline includes biosimilars of Humira, Avastin, and Lucentis.

Recommended Story: Why does the United States have a lingering trade deficit?

Insider Buying and Selling by Quarter for Coherus BioSciences (NASDAQ:CHRS)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Featured Article: What member countries make up the G-20?


7 Electric Vehicle (EV) Stocks That Are Ready to Rebound

The electric vehicle (EV) sector was nearly as frothy as the “pandemic stocks” in 2020. It wasn’t that the EV sector was dormant during the Trump administration.

But, as the saying goes, elections have consequences. And Wall Street understands they can make money in any administration. And as a bet that Joe Biden would win the presidency, electric vehicle stocks soared.

For starters, the Biden administration has already said it will prioritize climate change like no administration ever has. And one way they are going to do that is to incentivize the production and purchase of electric vehicles.

And to take advantage of this shift towards electric vehicle stocks, many private companies raced to get in on the action. The preferred way for many of these companies to go public was via a Special Purpose Acquisition Company (SPAC). A SPAC is basically a shortcut to the traditional IPO process.

However, what goes up frequently goes down and since late February, EV stocks have been getting battered. But this is creating an opportunity because the electric vehicle is still supposed to see exceptional growth over the next five years.

To help you take advantage of this we’ve created this special presentation that includes seven stocks that appear to be ready to take the next leg up.

View the "7 Electric Vehicle (EV) Stocks That Are Ready to Rebound ".


MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.